Magnetoliposomes Containing Multicore Nanoparticles and a New Antitumor Thienopyridine Compound with Potential Application in Chemo/Thermotherapy

• Main Authors: Almeida, B.G (Author), Araújo, J.P (Author), Castanheira, E.M.S (Author), Coutinho, P.J.G (Author), Fernandes, A.V.F (Author), Lopes, F.A.C (Author), Pereira, A.M (Author), Pires, A. (Author), Queiroz, M.-J.R.P (Author), Rodrigues, A.R.O (Author), Rodrigues, J.M (Author)
• Format: Article
• Language: English
• Published: MDPI 2022
• Subjects: antitumor thienopyridine derivative; chemotherapy; magnetic hyperthermia; magnetoliposomes; multicore magnetic nanoparticles
• Online Access: View Fulltext in Publisher

 Multicore magnetic nanoparticles of manganese ferrite were prepared using carboxymethyl dextran as an agglutinating compound or by an innovative method using melamine as a cross-coupling agent. The nanoparticles prepared using melamine exhibited a flower-shape structure, a saturation magnetization of 6.16 emu/g and good capabilities for magnetic hyperthermia, with a specific absorption rate (SAR) of 0.14 W/g. Magnetoliposome-like structures containing the multicore nanoparticles were prepared, and their bilayer structure was confirmed by FRET (Förster Resonance Energy Transfer) assays. The nanosystems exhibited sizes in the range of 250–400 nm and a low polydispersity index. A new antitumor thienopyridine derivative, 7-[4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl]thieno[3,2-b]pyridine, active against HeLa (cervical carcinoma), MCF-7 (breast adenocarcinoma), NCI-H460 (non-small-cell lung carcinoma) and HepG2 (hepatocellular carcinoma) cell lines, was loaded in these nanocarriers, obtaining a high encapsulation efficiency of 98 ± 2.6%. The results indicate that the new magnetoliposomes can be suitable for dual cancer therapy (combined magnetic hyperthermia and chemotherapy). © 2022 by the authors. Licensee MDPI, Basel, Switzerland.